

## References

### I-94

1. Eylea® (aflibercept) injection, for intravitreal use [package insert]. Regeneron Pharmaceuticals, Inc. Tarrytown, NY. Revised 12/2023.
2. Macugen® (pegaptanib sodium injection) injection, for intravitreal use [package insert]. Bausch + Lomb Inc., Bridgewater, NJ. Revised 07/2016.
3. Lucentis® (ranibizumab injection) injection, for intravitreal use [package insert]. Genentech, Inc., South San Francisco, CA. Revised 02/2024.
4. Jetrea® (ocriplasmin) injection, for intravitreal use [package insert]. ThromboGenics Inc., Iselin, NJ. Revised 02/2017.
5. Avastin (bevacizumab) injection, for intravitreal use [package insert]. Genentech, Inc., South San Francisco, CA. Revised 09/2022.
6. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. aflibercept.
7. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. pegaptanib sodium.
8. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. ranibizumab injection.
9. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. ocriplasmin.
10. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. bevacizumab.
11. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Brolucizumab-dbl.
12. Beovu® (brolucizumab-dbl) injection, for intravitreal use [package insert]. Novartis Pharmaceuticals Corp., East Hanover, NJ. Revised 07/2024.
13. Micromedex DrugDex Compendium®. 2024. Bevacizumab.
14. Dugel P, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double[1]masked trials of brolucizumab for neovascular age-related macular Degeneration. *Ophthalmology*. 2020;127:72-84.
15. Cheung C, Arnold J, Holz F, et al. Myopic choroidal neovascularization: review, guidance, and consensus statement on management. *Ophthalmology*. 2017;124:1690-1711.
16. Micromedex DrugDex Compendium®. 2024. Brolucizumab.
17. Micromedex DrugDex Compendium®. 2024. Ranibizumab.
18. Micromedex DrugDex Compendium®. 2024. Pegaptanib.
19. Micromedex DrugDex Compendium®. 2024. Aflibercept.
20. Micromedex DrugDex Compendium®. 2024. Ocriplasmin.
21. Micromedex DrugDex Compendium®. 2024. Faricimab-svoa.

22. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Faricimab
23. Susvimo™ (ranibizumab injection) intravitreal injection via ocular implant [package insert]. Genentech Inc., South San Francisco, CA. Revised 4/2022.
24. Byooviz® (ranibizumab-nuna) injection, for intravitreal use [package insert] Biogen Inc., Cambridge, MA. Revised 10/2023.
25. Vabysmo™ (faricimab-svoa) injection, for intravitreal use [package insert]. Genentech Inc., South San Francisco, CA. Revised 07/2024.
26. Aflibercept In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 1, 2022.
27. Brolucizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 20, 2020.
28. Faricimab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 10, 2024.
29. Ocriplasmin In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated June 10, 2024.
30. Pegaptanib In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 1, 2009.
31. Ranibizumab. In: AHFS Drug Information Online Electronic Medical Library.
32. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 1, 2022.
33. Khanani AM, Patel SS, Ferrone PJ, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: The STAIRWAY phase 2 randomized clinical trial. *JAMA Ophthalmol.* 2020;138(9):964-972.
34. Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD Phase 2 randomized trial. *Ophthalmology.* 2019;126(8):1155-1170.
35. Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: A randomized clinical trial. *JAMA Ophthalmol.* 2021;139(1):68-76.
36. Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. *Ophthalmology.* 2022;129(3):295-307.

37. Cimerli™ (ranibizumab-eqrn) injection, for intravitreal use [package insert]. Coherus BioSciences, Inc. Redwood City, CA. Revised 05/2024.
38. Syfovre™ (pegcetacoplan injection), for intravitreal use [package insert]. Apellis Pharmaceuticals, Inc. Waltham, MA. Revised 02/2023.
39. Micromedex DrugDex Compendium®. 2024. pegcetacoplan
40. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Pegcetacoplan.
41. Pegcetacoplan. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. June 10, 2024.
42. Izervay™ (avacincaptad pegol intravitreal solution) [package insert]. Iveric bio, Inc. Parsippany, NJ. Revised 02/2024.
43. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: A randomized pivotal phase 2/3 trial. *Ophthalmology*. 2021;128:576–86
44. ClinicalTrials.gov. A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration. ClinicalTrials.gov Identifier: NCT04435366. Available at: <https://clinicaltrials.gov/ct2/show/NCT04435366>(accessed 10 September 2023).
45. ClinicalTrials.gov. A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. ClinicalTrials.gov Identifier: NCT02686658. Available at: <https://clinicaltrials.gov/ct2/show/NCT02686658>(accessed 10 September 2023).
46. Micromedex DrugDex Compendium®. 2024. Avacincaptad Pegol.
47. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Avacincaptad Pegol.
48. Eylea® HD (aflibercept) injection, for intravitreal use [package insert]. Regeneron Pharmaceuticals, Inc. Tarrytown, NY. Revised 12/2023.
49. Scott IU, Campochiaro PA, Newman NJ, Biousse V. Retinal vascular occlusions. *Lancet*. 2020;396:1927– 1940.
49. Hattenbach LO, Abreu F, Arrisi P, et al. BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale. *Ophthalmol Sci*. 2023;3(3):100302.
50. Pavblu™ (aflibercept-ayyh) injection, for intravitreal use [package insert]. Amgen Inc., Thousand Oaks, CA. Revised 08/2024.
51. Clinical Pharmacology™ Compendium. 2025. Tampa FL: Gold Standard, Inc. Aflibercept.

52.Micromedex DrugDex Compendium®. 2025. Aflibercept-ayyh.